Annals of HematologyPub Date : 2026-10-28Epub Date: 2026-10-30DOI: 10.1007/s00277-026-07277-6
Ihab Karim, Tobias Arnold, Andreas Bräuninger, Marius Dohse, Felix Schell, Maisun Abu Samra, Thomas Tarawneh, Andreas Burchert, Stefan Gattenlöhner, Kristina Sohlbach
{"title":"Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma","authors":"Ihab Karim, Tobias Arnold, Andreas Bräuninger, Marius Dohse, Felix Schell, Maisun Abu Samra, Thomas Tarawneh, Andreas Burchert, Stefan Gattenlöhner, Kristina Sohlbach","doi":"10.1007/s00277-026-07277-6","DOIUrl":"10.1007/s00277-026-07277-6","url":null,"abstract":"<div><p>Histiocytic sarcoma is a rare and aggressive malignancy with poor outcomes under conventional chemotherapy. Activating <i>MAPK</i> pathway alterations, including <i>BRAF V600E</i> mutations, provide a rationale for targeted therapy; however, the durability of responses and the role of post-transplant maintenance remain unclear. We report a patient with refractory <i>BRAF V600E</i>-mutant histiocytic sarcoma who achieved complete remission following <i>BRAF/MEK</i> inhibition and subsequently underwent allogeneic stem cell transplantation. Post-transplant maintenance therapy with dabrafenib and trametinib was initiated early after engraftment. The patient achieved sustained complete remission with no radiological or molecular evidence of disease during follow-up exceeding one year. Circulating tumor DNA analysis remained negative for previously detected mutations. This case suggests that an integrated strategy combining targeted therapy, allogeneic transplantation, and post-transplant maintenance may enable durable disease control in high-risk <i>BRAF</i>-mutant histiocytic sarcoma and warrants further evaluation.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149293979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seok Lee, Hyeoung-Joon Kim, June-Won Cheong, Ho-Jin Shin, Jee Hyun Kong, Sang Kyun Sohn, Sung-Soo Yoon, Dae Young Zang, Chul Won Jung, Jeong-A Kim, Sung-Eun Lee, Won Sik Lee, Yunsuk Choi, Inho Kim, Jae Joon Han, Min Kyoung Kim, So Young Chong, Da Jung Kim, Deog-Yeon Jo, Hawk Kim, Jae-Yong Kwak, Je-Hwan Lee, Jieun Uhm, Sewon Lee, Min-Yi Lee, Dong-Wook Kim
{"title":"Correction to: Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","authors":"Seok Lee, Hyeoung-Joon Kim, June-Won Cheong, Ho-Jin Shin, Jee Hyun Kong, Sang Kyun Sohn, Sung-Soo Yoon, Dae Young Zang, Chul Won Jung, Jeong-A Kim, Sung-Eun Lee, Won Sik Lee, Yunsuk Choi, Inho Kim, Jae Joon Han, Min Kyoung Kim, So Young Chong, Da Jung Kim, Deog-Yeon Jo, Hawk Kim, Jae-Yong Kwak, Je-Hwan Lee, Jieun Uhm, Sewon Lee, Min-Yi Lee, Dong-Wook Kim","doi":"10.1007/s00277-026-07311-7","DOIUrl":"10.1007/s00277-026-07311-7","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07311-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of HematologyPub Date : 2026-10-24Epub Date: 2026-10-26DOI: 10.1007/s00277-026-07333-1
Lynn Leppla, Sabine Valenta, Kris Denhaerynck, Anja Schmid, Janette Ribaut, Alexandra Teynor, Thomas Meyer, Claudia Wehr, Robert Zeiser, Sabine Gerull, Jörg Halter, Jakob Passweg, Sabina De Geest
{"title":"Evaluating the effectiveness of the eHealth-faciLitated SMILe–integrated care model on treatment burden, quality of life and graft-versus-host disease after allogeneic stem cell transplantation: results of two European randomized controlled implementation studies","authors":"Lynn Leppla, Sabine Valenta, Kris Denhaerynck, Anja Schmid, Janette Ribaut, Alexandra Teynor, Thomas Meyer, Claudia Wehr, Robert Zeiser, Sabine Gerull, Jörg Halter, Jakob Passweg, Sabina De Geest","doi":"10.1007/s00277-026-07333-1","DOIUrl":"10.1007/s00277-026-07333-1","url":null,"abstract":"<div><p>The SMILe Integrated Care Model (SMILe–ICM) has previously demonstrated feasibility, successful implementation, and promising effects on survival, re-hospitalization, and cost-effectiveness following allogeneic stem cell transplantation (alloSCT). To complement these findings and provide a more comprehensive evaluation of the intervention’s effects, we evaluated patient-reported and clinical secondary outcomes from two RCTs. Data from two hybrid effectiveness-implementation RCTs conducted at two European alloSCT centers (Germany, Switzerland) were analyzed. Adult alloSCT recipients were randomized 1:1 to usual care (UCG) or the SMILe–ICM, a multicomponent intervention combining eHealth with advanced practice nurse-led self-management support. Treatment burden was assessed using the Patients’ Experience of Treatment and Self-Management (PETS 2.0), HRQoL using the EQ-5D-5 L, and GvHD outcomes using EBMT-registry data. Analyses followed an intention-to-treat approach. The current study examined data from 152 patients (76 SMILe–ICM, 76 UCG). Treatment burden was lower in the SMILe–ICM group, with significant differences in five dimensions. Both groups’ HRQoL improved over time without significant between-group differences. The cumulative incidence of acute GvHD was lower in the SMILe–ICM group than in the UCG (34.2% vs. 55.3%; HR 0.54, 95% CI 0.33–0.88; <i>p</i> = 0.01); chronic GvHD did not differ significantly (<i>p</i> = 0.64). SMILe–ICM reduced treatment burden and was associated with a lower cumulative incidence of grades II–IV acute GvHD, while HRQoL and chronic GvHD did not differ significantly between groups. The acute GvHD finding warrants further investigation to determine whether and through which pathways integrated APN-led survivorship care may influence post-alloSCT clinical outcomes.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nils Schulze, Moritz Lehne, Anja Cengia, Klara Sonnie Hinrichsmeyer, Agnes Kisser, Ferras Alashkar, Caoimhe Cawley
{"title":"Sickle cell disease in Germany – trends in epidemiology, healthcare utilization and disease burden from 2015 to 2024: a claims data analysis","authors":"Nils Schulze, Moritz Lehne, Anja Cengia, Klara Sonnie Hinrichsmeyer, Agnes Kisser, Ferras Alashkar, Caoimhe Cawley","doi":"10.1007/s00277-026-07308-2","DOIUrl":"10.1007/s00277-026-07308-2","url":null,"abstract":"<div><p>Background: Sickle cell disease (SCD) is a rare inherited hemoglobinopathy associated with substantial morbidity and high healthcare needs. In Germany, population-based evidence on SCD epidemiology and real-world care patterns remains limited, despite increasing relevance in the context of migration and the introduction of nationwide newborn screening in 2021. Methods: We conducted a retrospective, non-interventional study using anonymized German statutory health insurance claims data from the InGef database (2015–2024). Patients with SCD were identified using ICD-10-GM codes D57.0, D57.1, D57.2, and D57.8 based on inpatient and confirmed outpatient diagnoses. Administrative prevalence was estimated using a carry-forward cohort approach, whereby SCD patients diagnosed in the current year and alive/observable in subsequent years were counted as prevalent. Administrative incidence was assessed in children aged < 6 years using the first recorded SCD diagnosis in claims data as the date of incidence. Analyses of patient characteristics, clinical outcomes, treatments and healthcare resource use (HCRU) were conducted cross-sectionally by calendar year, stratified by age group and sex. Results: Across 2015–2024, 1,019 individuals with SCD were identified. As might be expected using a carry forward cohort approach, annual prevalent counts increased from 225 (2015) to 864 (2024), and nationally extrapolated prevalence increased from 2.75 per 100,000 in 2015 to 10.50 per 100,000 in 2024. Median time to recorded diagnosis in children < 6 years decreased from 31 months (2015) to 11 months from 2021 onwards (2021–2024). In 2024, infections were the most frequently documented clinical outcome (34.5% [298/864]), followed by vaso‑occlusive crises (19.2% [166/864]) and mental health comorbidities (depression 19.1% [165/864]; anxiety 9.1% [79/864]). The proportions of patients with inpatient or outpatient visits, and with medication prescriptions (e.g. for antibiotics, antirheumatics, hydroxyurea), decreased over time. Conclusion: This claims-based analysis indicates increasing documented SCD prevalence in Germany. However, the extent to which prevalence increased due to a true increase in the general population, due to our carry-forward cohort approach, or due to other factors such as changes in coding practices or healthcare seeking behaviors, cannot be disentangled.We observed earlier recorded diagnosis timing in young children over time, alongside substantial age-dependent burden reflected in complications, mental health comorbidity, and healthcare utilization. Possible explanations for lower proportions of patients with inpatient/outpatient visits and medication prescriptions over time may include changes in disease awareness, patient management and/or healthcare seeking behaviours over time, and/or broader capture of patients with milder disease. Overall, our findings can inform healthcare planning and structured life-course–oriented SCD care p","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07308-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149235049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matilda Arvidsson Kvissberg, Christer Nilsson, Niklas Landberg, Albin Österroos, Aristea Papageorgiou, Bertil Uggla, Vladimir Lazarevic, Stefan Deneberg, Martin Jädersten
{"title":"Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML","authors":"Matilda Arvidsson Kvissberg, Christer Nilsson, Niklas Landberg, Albin Österroos, Aristea Papageorgiou, Bertil Uggla, Vladimir Lazarevic, Stefan Deneberg, Martin Jädersten","doi":"10.1007/s00277-026-07297-2","DOIUrl":"10.1007/s00277-026-07297-2","url":null,"abstract":"<div><p><i>FLT3-</i>mutated acute myeloid leukemia (AML) is associated with high relapse rates and treatment resistance. Triplet therapy with azacitidine (AZA), venetoclax (VEN), and the FLT3 inhibitor gilteritinib (GILT) yields high response rates but is limited by myelosuppression and infections. We conducted a multicenter retrospective study of 29 <i>FLT3</i>-mutated AML patients treated with GILT-triplets. The primary endpoint was overall survival (OS); secondary endpoints event-free survival (EFS) and time to neutrophil and platelet recovery. Patients received one of three regimens: concomitant triplet therapy (Group 1); concomitant AZA + VEN followed by concomitant VEN+GILT (Group 2); or overlapping AZA + VEN followed by GILT monotherapy (Group 3). For the entire cohort median OS was not reached after more than five years of follow-up. High response rates were observed across all schedules. Limiting concomitant exposure reduced myelosuppression and decreased infectious complications compared with full triplet therapy. Median OS was not reached in Groups 1 and 2 after three years, whereas Group 3 had a median OS of 18 months. Median EFS was 40.5 months in Group 1 and was not reached at five years in Group 2, compared with 11.5 months in Group 3. Our data suggest that reducing the duration of triple-drug overlap may improve tolerability without compromising clinical outcomes.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07297-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149235050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ingerid Weum Abrahamsen, Anders Eivind Myhre, Camilla Dao Vo, Tobias Gedde-Dahl, Tor Henrik Tvedt
{"title":"Epstein-barr virus-associated hemophagocytic lymphohistiocytosis after antithymocyte globulin-conditioned allogeneic hematopoietic stem cell transplantation: a single-center case series","authors":"Ingerid Weum Abrahamsen, Anders Eivind Myhre, Camilla Dao Vo, Tobias Gedde-Dahl, Tor Henrik Tvedt","doi":"10.1007/s00277-026-07307-3","DOIUrl":"10.1007/s00277-026-07307-3","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07307-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kürsat Kirkgöz, Katja Weisel, Carsten Bokemeyer, Susanne von Kroge
{"title":"Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature","authors":"Kürsat Kirkgöz, Katja Weisel, Carsten Bokemeyer, Susanne von Kroge","doi":"10.1007/s00277-026-07303-7","DOIUrl":"10.1007/s00277-026-07303-7","url":null,"abstract":"<div><p>Primary thyroid diffuse large B-cell lymphoma (DLBCL) is a rare subset of primary extranodal DLBCL. Thus, there are limited evidence-based specific recommendations regarding its diagnosis and treatment. We present a case report of a patient with relapsed primary thyroid DLBCL, followed by a focused literature review covering key epidemiological, diagnostic, and therapeutic aspects. In 2017, a 74-year-old woman was diagnosed with primary thyroid non-GCB-type DLBCL (Ann Arbor IE, IPI 2) after presenting with dyspnoea, hoarseness, and cough. Treatment with R-CHOP and CNS prophylaxis achieved complete remission. Six years later, an isolated relapse occurred in the contralateral thyroid gland. The patient was treated with Pola-R-miniCHP (off-label), resulting in complete remission again. In the focused literature review core needle or surgical biopsy was found to be important for reliable histopathological characterization, while first-line treatment mainly consisted of rituximab-containing chemoimmunotherapy, occasionally combined with radiotherapy. Surgery was largely limited to diagnostic purposes. Reported 5-year overall survival rates ranged from 57% to 88%, whereas relapse or refractory disease and central nervous system involvement were rare. Registry-based studies, especially those focusing on primary extranodal DLBCL, are necessary to develop evidence-based treatment guidelines for these patients.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07303-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of HematologyPub Date : 2026-10-08Epub Date: 2026-10-09DOI: 10.1007/s00277-026-07302-8
Karin Potthoff, Jens Uhlig, Eyck von der Heyde, Christoph Losem, Arnd Nusch, Andreas Ammon, Björn Schöttker, Holger Schulz, Jan Janssen, Manfred Welslau, Stefan Wilop, Corinne Vannier, Johanna Hanselmann, Laura Serrer, Sandra M. Woerner, Sophie Koszinowski, Monika Engelhardt, Wolfgang Knauf
{"title":"Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma","authors":"Karin Potthoff, Jens Uhlig, Eyck von der Heyde, Christoph Losem, Arnd Nusch, Andreas Ammon, Björn Schöttker, Holger Schulz, Jan Janssen, Manfred Welslau, Stefan Wilop, Corinne Vannier, Johanna Hanselmann, Laura Serrer, Sandra M. Woerner, Sophie Koszinowski, Monika Engelhardt, Wolfgang Knauf","doi":"10.1007/s00277-026-07302-8","DOIUrl":"10.1007/s00277-026-07302-8","url":null,"abstract":"<div><p>The prospective, multicenter, non-interventional study CARO (NCT02970747) investigated adherence, effectiveness, quality of life and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in German routine clinical practice. CARO included 359 patients at 69 sites and evaluated three carfilzomib-based treatment regimens: Carfilzomib with lenalidomide and dexamethasone (KRd), with dexamethasone only (Kd) or with daratumumab and dexamethasone (KdD). Across cohorts, patients’ adherence to carfilzomib was > 90%, while effectiveness was in line with previous data from both randomized clinical trials and real-world studies. Median PFS (95% CI) was 17.5 months (14.5, 24.7 [KRd]), 13.4 months (7.3, 18.1 [Kd]) and 20.1 months (10.9, 26.6 [KdD]), respectively. Median OS was 38.9 months (31.5, 51.4 [KRd]), 24.6 months (17.8, 36.8 [Kd]) and not reached (21.9, NA [KdD]). Patients’ quality of life remained stable during treatment, while pain parameters improved after 6 months of treatment. CARO provides real-world evidence that KRd, Kd, and KdD combinations achieve clinically meaningful outcomes in everyday practice and demonstrates patients’ excellent treatment adherence.</p><p>ClinicalTrials.gov identifier: NCT02970747</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07302-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study","authors":"Xiaohui Xiao, Guiping Chen, Cong Xu, Liangliang Wu, Xiaoyan Liu, Ming Zhou, Xiaowei Chen, Ruiqing Zhou, Wenjian Mo, Yumiao Li, Shilin Xu, Yuping Zhang, Dongjun Lin, Shunqing Wang","doi":"10.1007/s00277-026-07289-2","DOIUrl":"10.1007/s00277-026-07289-2","url":null,"abstract":"<div><p>Immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IST+EPAG) is the preferred first-line treatment for severe aplastic anemia (SAA) patients over 40 years. However, direct comparison between IST+EPAG and upfront haploidentical hematopoietic stem cell transplantation (HID-HSCT) in this population remains limited. We retrospectively analyzed 123 newly diagnosed SAA patients aged 40–65 who received first-line HID-HSCT (<i>n</i> = 67) or IST+EPAG (<i>n</i> = 56) between 2016 and 2024. Hematological response, survival, and safety were compared. The HID-HSCT group demonstrated superior complete response (CR) rates at 3 months (17.9% vs. 5.4%), 6 months (44.8% vs. 17.9%), and 12 months (64.2% vs. 33.9%) (all <i>P</i> < 0.001). The 3-year overall survival (OS) was comparable between the HID-HSCT and IST+EPAG groups (78.0% vs. 80.3%, <i>P</i> = 0.662), and a landmark analysis conditional on survival to 6 months confirmed comparable subsequent 3-year OS (92.2% vs. 88.9%, <i>P</i> = 0.616). Meanwhile, the 3-year failure-free survival (FFS) was significantly higher in the HID-HSCT group among patients aged 40–49 (82.9% vs. 60.1%, <i>P</i> = 0.045), whereas no difference was observed in those aged 50–65 (<i>P</i> = 0.984). HID-HSCT may offer more durable benefits in selected SAA patients aged 40–49, while its advantage over IST+EPAG is not evident in patients aged 50–65.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 11","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07289-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation","authors":"Jiayuan Guo, Liuqing Huang, Zixuan Li, Andi Zhang, Meng Li, Linlin Zhang, Lu Wang, Fei Li, Lili Wang, Yu Jing, Jian Bo, Daihong Liu, Liping Dou, Zhenyang Gu, Chunji Gao","doi":"10.1007/s00277-026-07295-4","DOIUrl":"10.1007/s00277-026-07295-4","url":null,"abstract":"<div><p>Although T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) were historically regarded as different manifestations of a single disease entity driven by immature T-lymphoblast proliferation, recent advances in molecular diagnostics and cytogenetic testing have revealed inherent differences in their molecular signatures and chromosomal profiles. Despite these differences, comparative data on clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT) between the two subtypes remain limited. To address this gap, we retrospectively analyzed 106 consecutive patients, including 71 with T-ALL and 35 with T-LBL, who underwent allo-HSCT at our institution between January 2010 and January 2025. No statistically significant differences were observed in overall survival (OS), disease-free survival (DFS), graft-versus-host disease–free, relapse-free survival (GRFS), cumulative incidence of relapse (CIR), or cumulative incidence of non-relapse mortality (NRM) between patients with T-ALL and T-LBL. Diagnosis was not associated with these outcomes in multivariable analyses. However, the association between diagnosis and OS, DFS, CIR, and NRM varied over time. At 6 months, the multivariable analysis showed worse OS in T-LBL (hazard ratio at the specified time [HR(t)], 2.41; 95% confidence interval [CI], 1.10–5.28; <i>P</i> = 0.028). At 36 months, T-LBL was associated with lower risks of DFS failure (HR(t), 0.16; 95% CI, 0.03–0.91; <i>P</i> = 0.039) and NRM (subdistribution hazard ratio at the specified time [sHR(t)], 0.06; 95% CI, 0.01–0.72; <i>P</i> = 0.026). The 36-month restricted mean survival time (RMST) for OS was 5.79 months shorter in T-LBL (95% CI, − 11.38 to − 0.19; <i>P</i> = 0.043), whereas DFS and GRFS RMST did not differ significantly. Results for most outcomes did not differ significantly between groups in either the PSM cohorts or the first complete remission subgroup, although moderate to severe chronic graft-versus-host disease (cGVHD) was less frequent in T-LBL. Complete case analyses for white blood cell (WBC) and lactic dehydrogenase (LDH) and analyses restricted to patients in complete remission with evaluable measurable residual disease (MRD) did not materially alter the diagnosis estimates. Overall, OS, DFS, CIR, NRM, and GRFS did not differ significantly between patients with T-ALL and T-LBL, although the effects of diagnosis on OS, DFS, CIR, and NRM changed during follow-up. These findings should be interpreted cautiously and confirmed in larger multicenter studies.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07295-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149339203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}